Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.
Join Heather Mambretti, PA-C, a rheumatology specialist in Houston, Texas, as she explores the critical role of IL-23 in autoimmune disease pathogenesis and how IL-23 inhibitors have revolutionized treatment strategies for psoriasis, psoriatic arthritis (PsA), and inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
IL-23 is a key cytokine produced by dendritic and macrophage cells, driving TH17 cell differentiation and fueling chronic inflammation. In psoriasis and PsA, dysregulated IL-23 signaling promotes TH17 proliferation, leading to increased IL-17A and IL-17F production—major contributors to inflammation in skin and joints. In IBD, IL-23 plays a similar role, disrupting intestinal barrier integrity and perpetuating chronic inflammation in conditions like Crohn’s disease and ulcerative colitis.
Targeting IL-23 with selective inhibitors has transformed the treatment landscape, offering a precise approach that reduces TH17-driven inflammation while preserving broader immune function. Clinical evidence, including a 2021 Rheumatology Journal publication, underscores IL-23’s pivotal role as the key link between skin, gut, and joint inflammation, making IL-23 inhibition an essential strategy in managing these autoimmune conditions.
IL-23 inhibitors provide effective, targeted therapy, reducing systemic inflammation, improving symptoms, and enhancing long-term patient outcomes across multiple inflammatory diseases.
For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.
Related FAQ Video Module
